New cancer drug combo shows promise in early trial

NCT ID NCT04710043

Completed Disease control Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested two experimental drugs, BNT152 and BNT153, alone and together in 86 adults with advanced solid tumors that had spread or could not be removed and had no standard treatment options. The main goal was to check safety and find the best dose. Researchers also looked for signs that the drugs were working against the tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Duke Cancer Center

Durham, North Carolina, 27710, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Masaryk Memorial Cancer Institute

Brno, 65653, Czechia
NEXT Oncology

San Antonio, Texas, 78229, United States
Robert H. Lurie Comprehensive Cancer Center, Northwestern University

Chicago, Illinois, 60611, United States
Sarah Cannon Research Institute at Tennessee Oncology

Nashville, Tennessee, 37203, United States
Yale Cancer Center

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.